ALK treatment considerations in NSCLC

TOGA Podcast

English - December 08, 2021 09:10 - 29 minutes - 26.9 MB
Medicine Health & Fitness lung cancer oncology toga Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Stigma and Nihilism In Lung Cancer : A Call to Action

Next Episode: The need for a National Clinical Quality Registry in Lung Cancer

Welcome to the Thoracic Oncology Group of Australasia Podcast series. Today Mal Itchins, Medical Oncologist from Royal North Shore Hospital discusses ALK therapy choices & considerations when treating ALK NSCLC. Mal is joined by Steven Kao, Medical Oncologist from the Chris O’Brien Lifehouse and Lisa Briggs who has her own personal experience with ALK lung cancer having been diagnosed in 2014, when only limited treatment options were available

We have seen rapid transformation in treating ALK lung cancer with emerging therapies and new indications over the last decade. We discuss how to choose one treatment over another, optimizing sequencing as well as addressing potential side effects associated with each of the options. Patient preferences, needs and wants are also considered.

Two of the associated TOGA trials, ASPiRATION and ALKternate are exploring how molecular testing can monitor emerging mutations and influence treatment decisions, as well as exploring liquid biopsy to search for emerging mechanisms of resistance.

https://thoraciconcology.org.au/clinical-trials/

Thank you to Pfizer for sponsoring this Podcast.

Disclaimer: The opinions, beliefs and viewpoints expressed by the various authors and participants contained in this message do not necessarily reflect the opinions, beliefs and viewpoints of TOGA or official policies of TOGA. Dosage & administration of any treatments mentioned during TOGA medical education may differ between Regions. Please refer to your local prescribing information for further details.